UCL Upper GI Symposium (UGIS) 2020
- 250 Euston Road, London, NW12BU
- 8:15 am - 4:30 pm
Autoimmune liver diseases (AILD) represent the greatest unmet need in modern hepatology, given their indeterminate aetiology, heterogeneous clinical presentations, and variable rates of clinical progression. AILD represent a leading indication for transplantation across the UK and Europe. Therapeutic options in autoimmune hepatitis whilst effective are imprecise and accompanied by a significant impact on patient quality of life.
Primary biliary cholangitis, the commonest of all three diseases, can be treated effectively with timely access to bile acid therapy; however, underdosing is common, and therapeutic shortfall evident in up to a third of patients. Primary sclerosing cholangitis is perhaps the greatest challenge in clinical practice, for which liver transplantation remains the only life-saving intervention.
This meeting presents a contemporary overview of evidence-based clinical practice and research activity in AILD. Each speaker is a key opinion leader in their field, with coverage of topics that encompass risk stratification, timing and choice of therapeutic strategies, clinical trial updates, and management considerations in special populations.
You will able to learn and discuss the following:
To register for this Falk Forum please visit the Dr Falk Pharma website. Please complete all required fields in the registration form including any dietary requirements and ensure you click the “submit” button. You will receive an email confirming your registration within 24 hours.
This forum has been endorsed by the BSG Education Committee. It has been approved by the Federation of The Royal Colleges of Physicians of the United Kingdom for 5 CPD credits.